A relatively new test, called AFP-L3%, is sometimes also ordered to compare the amount of total AFP to the amount of one of the AFP variants called AFP-L3. The AFP-L3% test is not yet widely used in the U.S. but has gained wider acceptance in other countries such as Japan. The test is used to help evaluate the risk of developing hepatocellular carcinoma, especially in those with chronic liver disease. An increase in the percentage of L3 to total AFP indicates an increased risk of rapidly developing this disease and also of having less chance of survival.

This test requires that we locate a collection site near you CLICK HERE